LUNG Pulmonx Corporation

NASDAQ
$2.80

Pulmonx Corporation (LUNG) is expected to report earnings on January 26, 2027, after the market close. The consensus earnings estimate is a loss of $0.23 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +18.1% since its last earnings release on October 27, 2026.

Pulmonx Beat Expectations, Reaffirms Revenue Guidance
Tuesday, October 27, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Jan 26
Tuesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.23)
Rev est $24.95M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.79

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Pulmonx Corporation

Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX™ Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic.

Sector

Healthcare

Industry

Medical Instruments/Supply

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.